Health Expenses and Outcomes of the DASH Diet in Egyptian Patients With Hypertension

Beni-Suef University

Status: Completed

Conditions: Hypertension,Essential

Treatments: Other: DASH diet

Study type: Interventional

Funder types: Other

Identifiers

NCT06499194

DASH diet and hypertension

Details and patient eligibility

About

DASH diet can reduce hypertension and decrease health expenses

Full description

Hypertension is a prevalent cardiovascular risk factor associated with adverse outcomes and obesity. Egypt's prevalence is 26.3%, exceeding rates in the U.S. and sub-Saharan Africa. Lifestyle interventions like the DASH diet effectively manage hypertension, offering a cost-effective alternative to pharmacological treatments. This study aims to assess the effects of the DASH diet on blood pressure, BMI, waist circumference, and fasting blood glucose, as well as its cost-effectiveness compared to pharmacological treatments. This open-label prospective controlled clinical trial was conducted in Esna Health Administration, Luxor Governorate. The FMREC of Beni-Suef University approved the study, which included 364 hypertensive patients aged 30-60. Exclusions were patients with severe comorbidities or those who declined participation. Measurements included height, weight, BMI, blood pressure, and laboratory tests. The intervention group received a DASH diet education program. Outcomes measured were blood pressure, BMI, waist circumference, weight, and fasting blood glucose at baseline and post-intervention. Our study demonstrates the significant benefits of the DASH diet in managing blood pressure, weight, and fasting blood glucose levels in the Egyptian population. The DASH diet substantially reduced systolic and diastolic blood pressure, with a notable decrease in the number of antihypertensive medications needed. Additionally, participants on the DASH diet experienced significant weight loss and reduced BMI and waist circumference compared to the control group. The economic implications of the DASH diet are also promising, with a notable decrease in the total cost of therapy due to reduced medication costs.

Enrollment: 364 patients

Sex: All

Ages: 30 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients diagnosed with primary hypertension (all stages) in the family medicine units of Esna Health Administration, located in Luxor Governorate.
• Individuals between the ages of 30 and 60, of both male and female genders.

Exclusion criteria

• • Patients with cancer and either hepatic failure or renal impairment.

  • Patients diagnosed with diabetes, metabolic illness, or terminal organ failure.
  • A patient with severe or malignant hypertension.
  • Individuals who decline to partake in our research.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

364 participants in 2 patient groups, including a placebo group

intervention group

Active Comparator group

Description:

Participants will taken a medical history review, anthropometric assessments, and waist circumference measurements. Tests included hemoglobin levels, kidney and liver function tests, fasting blood glucose, and lipid profiles. Baseline antihypertensive medications will be recorded in an Excel sheet and taken DASH diet .

Treatment:

Other: DASH diet

control group

Placebo Comparator group

Description:

Participants will taken a medical history review, anthropometric assessments, and waist circumference measurements. Tests included hemoglobin levels, kidney and liver function tests, fasting blood glucose, and lipid profiles. Baseline antihypertensive medications will be recorded in an Excel sheet and without taken DASH diet .

Treatment:

Other: DASH diet